DarioHealth, a digital chronic condition management platform, announced it expanded its GLP-1 offering with prescribing capabilities, a move the company said will help it capture a larger share of the weight-loss market space.

The company also announced a collaboration with MediOrbis, a multi-specialty digital health provider, to add prescribing capabilities to Dario’s GLP-1 behavior change solution for a comprehensive medical weight loss program. 

In a statement, DarioHealth asserted that the market for GLP-1 medications is driven by blockbuster drugs like Novo Nordisk's Ozempic and Wegovy medications. Those medications, the company said, have changed how obesity and weight management are viewed. 

DarioHealth explained that the expanded offering provides an "end-to-end program that improves employee health outcomes" while at the same time helping to manage costs.

DarioHealth’s offering integrates behavior change programs with physician oversight, ensuring GLP-1 medications are prescribed to the right people and backed by sustainable lifestyle changes, the company said. 

Dario said this approach aims to prevent the cycle of weight regain after medication use, a major worry for individuals and employers. 

It says the prescribing capability allows the company to manage the entire weight-loss journey and maximize long-term results.

The direct-to-consumer market is a high-growth target that DarioHealth said it intends to pursue, and the company said its integrated solution could position it as a key digital health partner for employers, consumers and pharma companies.

THE LARGER TREND

In 2024, DarioHealth collaborated with an unnamed pharma company to leverage DarioConnect (formerly Twill Care) to advance its direct-to-consumer initiatives using Dario's engagement and navigation technologies. 

The aim of the alliance was to gather critical insights on patient outcomes and drug effectiveness with Dario Connect's community-building capabilities, thereby playing a role in increasing patient engagement.

DarioHealth entered into a contract with a national Medicare Advantage health plan and plans to launch a behavioral health initiative, Twill by Dario, for the plan's members in January. Dario's platform and set of solutions provide data analytics and one-on-one coaching for a variety of health conditions, including diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

In February 2024, DarioHealth acquired Twill, a digital therapeutics company, accompanied by $22.4 million equity financing. The integration expanded on Dario's holistic approach to managing chronic conditions including diabetes, hypertension and weight management, and aimed to boost member engagement and improve health outcomes. 

The enhanced features allowed Dario members to join peer-to-peer condition groups, interact with healthcare experts for advice and access customized educational content.

That same year DarioHealth entered into a new contract with a regional health plan in the Medicaid space, which was launched with the full suite of cardiometabolic solutions. The launch with the health plan marked the third Medicaid client for DarioHealth. 

Late last year, DarioHealth unveiled an AARP member benefit that provides members with digital behavioral health and well-being solutions from Twill by Dario. The new benefit is expected to launch this month for AARP members.